Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Contact persons
Help
DOI
PMC
 |
|
Open Access Green as soon as Postprint is submitted to ZB.
Re-irradiation in elderly patients with glioblastoma: A single institution experience.
J. Neuro-Oncol. 142, 327-335 (2019)
BackgroundRe-Irradiation (Re-RT) is an established treatment option for young patients with recurrent glioblastoma (GBM). Multiple reports show a low risk of side-effects as well as a good efficacy resulting in median survival times ranging from 5 to 18 months. Elderly patients, however, are underrepresented in reports about Re-RT. Even in the elderly, with concomitant radiochemotherapy and adjuvant chemotherapy, progression-free survival times now are approaching 6months or even longer.MethodsWe report on 25 consecutive patients with at least 65years of age treated with Re-RT for recurrent GBM. We analyzed the patient's files for the treatment regimens, side-effects and survival times. Survival times, as well as hazards, were calculated by the Kaplan Meier method as well as Cox-regression method, respectively.ResultsThe median overall survival was 6.9months, treatment was well tolerated with only minor side effects. Use of systemic treatments as well as the length of the interval between 1st -line radiotherapy and re-irradiation were associated with a favorable prognosis. The latter remained significant after multivariate analysis.ConclusionRe-RT of elderly GBM patients should not be withheld based purely on age since the treatment is safe and results in comparable survival times to younger patients. When counseling elderly patients with recurrent GBM, especially the length of the interval since 1st line radiotherapy should be considered as a prognostic factor and an additional systemic treatment option should be considered.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Scientific Article
Keywords
Glioblastoma ; Elderly ; Re-irradiation ; Recurrent Glioblastoma ; Overall Survival; Radiation Plus Temozolomide; Stereotactic Reirradiation; Prognostic Score; Patients Older; Radiotherapy; Validation; Therapy; Gliomas
ISSN (print) / ISBN
0167-594X
e-ISSN
1573-7373
Journal
Journal of Neuro-Oncology
Quellenangaben
Volume: 142,
Issue: 2,
Pages: 327-335
Publisher
Springer
Publishing Place
233 Spring St, New York, Ny 10013 Usa
Non-patent literature
Publications
Reviewing status
Peer reviewed
Institute(s)
Institute of Radiation Medicine (IRM)